Names and pronunciation
(Ue-pad′a-sye′ti-nib) Rinvoq
PDF page 1339
Loading InternPractice…
Drug reference
(Ue-pad′a-sye′ti-nib) Rinvoq
PDF page 1339
Func. class.: Immunomodulating agent
PDF page 1339
Chem. class.: Janus associated kinase (JAK) inhibitor
PDF page 1339
ACTION: Oral JAK inhibitor; Janus kinase, a tyrosine kinase enzyme that transmits signals arising from cytokine or growth factor–receptor interactions on the cellular membrane to influence cellular processes of immune cell function and hematopoiesis
PDF page 1339
USES: Treatment of rheumatoid arthritis
PDF page 1339
CONTRAINDICATIONS Hypersensitivity Precautions: AIDS, anemia, breastfeed- U ing, children, contraception requirements, corticosteroid use, diverticulitis, geriat- rics, GI perforation, hepatic disease, hepatitis B exacerbation, herpes, HIV, neu- tropenia, pregnancy, pregnancy testing, vaccination
PDF page 1339
Black Box Warning: Infection, new prima- ry malignancy, thrombosis, mortality, stroke Black Box Warning: Some serious infec- tions including sepsis may occur, may be fatal; patients with active infections should not be started on this product Black Box Warning: Thrombosis (DVT, PE, arterial thrombosis): Assess for symptoms and treat immediately, some have been fatal May reactivate hepatitis B in chronic carriers; may be fatal Black Box Warning: Identify latent TB before therapy; treat before starting this product Blood dyscrasias: CBC, differential periodically Black Box Warning: Assess for neoplas- tic disease (lymphomas/leukemia) moni- tor for these and skin cancer • Pregnancy/breastfeeding: use only if clearly needed, no well-controlled stud- ies; cautious use in breastfeeding, ex- creted in breast milk
PDF pages 1339, 1340
DOSAGE AND ROUTES • Adults: PO 15 mg daily with or without methotrexate or other nonbiologic DMARDs
PDF page 1339
Available forms: Extended release tab- let 15, 30, 45 mg
PDF page 1340
Administer: • Give with or without food • Swallow whole; do not split, crush, or chew
PDF page 1340
Assess: • RA: pain; stiffness; ROM; swelling of joints before, during treatment • Infections (fever, flulike symptoms, dyspnea, change in urination, redness/ swelling around any wounds)—stop treatment if present
PDF page 1340
Evaluate: • Therapeutic response: decreased in- flammation, pain in joints, decreased joint destruction
PDF page 1340
CLINICAL CONSIDERATIONS
PDF page 1340
Patient and caregiver information: • Not to take any live virus vaccines dur- ing treatment • To report signs of infection, TB imme- diately
PDF page 1340
• Adults: PO 15 mg daily with or without methotrexate or other nonbiologic DMARDs
PDF page 1339